Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that ...
Dogwood Therapeutics, Inc. (DWTX) is a small, development-stage biotechnology company headquartered in Alpharetta, Georgia. The company operates in the healthcare/biotechnology sector and is focused on turning insights about antiviral mechanisms and immune responses into candidate therapies for conditions characterized by persistent symptoms following viral infection or abnormal immune activation. A ...Dogwood Therapeutics, Inc. (DWTX) is a small, development-stage biotechnology company headquartered in Alpharetta, Georgia. The company operates in the healthcare/biotechnology sector and is focused on turning insights about antiviral mechanisms and immune responses into candidate therapies for conditions characterized by persistent symptoms following viral infection or abnormal immune activation.
A central theme of Dogwood’s pipeline is the use of fixed-dose combinations built around known antiviral agents paired with celecoxib. This combination approach is reflected in its two primary development candidates. IMC-1 is described as a precise fixed-dose combination of famciclovir and celecoxib, developed to target fibromyalgia. IMC-2 combines valacyclovir and celecoxib and is positioned to address the multi-symptom profile often associated with long COVID, including fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety.
The company also operates with a relatively lean headcount for a public biotech. Reported full-time employees were 8 as of December 31, 2025, which is consistent with early-stage operational models where resources are concentrated on research, clinical development planning, regulatory pathways, and partnering/financing rather than large-scale commercial activity.
From a product and commercialization perspective, Dogwood is best characterized as pre-commercial (development-stage). As a result, cost structure and financial performance are typically dominated by research and development and related corporate/clinical expenses rather than revenue from marketed drugs. The provided snapshot financial indicators (e.g., negative profitability metrics and free cash flow figures on a trailing-twelve-month basis) are consistent with many early-stage biotechnology companies that invest ahead of commercialization.
Leadership is provided by Greg Duncan, who serves as Chief Executive Officer and Chairman of the Board. Under this structure, the company’s “key people” emphasis is commonly aligned with scientific leadership, clinical development execution, and corporate governance that supports fundraising and program advancement.
Dogwood previously operated under a different corporate name (Virios Therapeutics, Inc.) and changed its name to Dogwood Therapeutics, Inc. in October 2024, reflecting a branding and strategic evolution. Looking ahead, the company’s main “wishes” in practical terms are likely to be continued progress through clinical and regulatory milestones for IMC-1 and IMC-2, the accumulation of supportive clinical evidence for its antiviral-immune combination strategy, and the ability to secure sufficient funding to sustain development while advancing its pipeline.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-34.3M
-177.4%
-131.2%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-15.6M
-77.7%
+21.3%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.2%
-99.1%
+3.5%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.76x
-47.1%
-33.6%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
